ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / KNSA / insiders
IONS (26) AMRX (71) ABVX (54) AXSM (35) ⌘ Pro Terminal β†’

Kiniksa Pharmaceuticals International plc (Class A) (KNSA) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$90.80 -1.56% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $90.76

Kiniksa Pharmaceuticals International plc (Class A) (KNSA) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (88.5% gross margin, 10% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B- β€’ BUY Cap $7.25B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KNSA Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is KNSA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Kiniksa Pharmaceuticals International plc (Class A) (NASDAQ: KNSA) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $90.80 (-1.56% 1D, market cap $7.25B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, KNSA ranks #68 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does KNSA compare to IONS and AMRX in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KNSA carries a Roarable B- (71/100 RQD), trailing P/E of 129.9x, gross margin of 88.5%, and ROIC of 9.9%. By comparison, IONS (Ionis Pharmaceuticals Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -20.9%, cap $7.23B) and AMRX (Amneal Pharmaceuticals Inc.) posts a B- grade (71/100 RQD, P/E 103.2x, ROIC 14.1%, cap $7.49B). Among the 5-stock peer group, ABVX leads on earnings multiple (32.8x) while AMRX leads on capital efficiency (14.1% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KNSA?
β–Ό

Per KNSA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001730430), Kiniksa Pharmaceuticals International plc (Class A) generated $677.6M in revenue (+60.1% YoY), $59.0M in net income, and $136.4M in free cash flow against $763.6M in total assets and $88.2M in total debt. Key quantitative strengths: Strong cash generator (88.5% gross margin)β€”profits are backed by real money, not accounting tricks. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $90.76 (-0.04%)🧬 Disciplined Float (+0.80% YoY Shares)βš™οΈ Cash Engine: 15/20 (B) β€’ 20.1% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY β€’ 68.4% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERBUY β€’ B-
025507510071
3-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw B- Β· Rk B
Cash (15)Whales (18)SEC (15)Macro (14)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE+5.8% Base Target
$113 Bull$96 Base$74 Bear
πŸ“¬ FREE KNSA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for KNSA)Realized 20D OHLCV Swing Band: Β±10.4%
Deterministic 5-Pillar Attribution (71/100 Composite)
πŸ” WHY KNSA SCORES 71/100 (B-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+18/20 pts (25% of score)

20D Institutional Volume Accumulation (Β±10.4% realized swing band)

β–² #2 Bullish Driver: Cash Engine Quality+15/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 20.1% FCF Margin ($136.4M FCF) & 88.5% Gross Margin

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (+0.80% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
63
Grade C+$78.84+1.1% Next Q
Q2 (-2Q)
66
Grade B-$79.70+19.4% Next Q
Q3 (-1Q)
68
Grade B-$95.18-4.6% Next Q
Current
71
Grade B-$90.80+6.8% Hist 90D Ξ±
Trajectory: C+ (63) β†’ B- (71)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

βš”οΈ Adversarial Opposing Case: Why the KNSA Bull Thesis Could Fail

Gideon Ashmere Forensic Desk β†’

Even with a 71/100 (B-) score, KNSA faces multiple-compression risk if 129.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Priced at 130x earningsβ€”high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($80.13) or 200D SMA ($61.05) invalidates the momentum regime and cuts Target Base ($96.11) toward Bear Floor ($74.46).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KNSAβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œKNSA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 71%NO 29%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

KNSA Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (KNSA)

No recent open-market Form 4 cluster sales or emergency dumps flagged on KNSA. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (KNSA Tape Review)

  • βœ“Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • βœ“Forensic Red-Light accounting & dilution traps to review on your watchlist
  • βœ“Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
KNSA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +57.58%β–² ASCENDING CHANNEL
2026-11-03O $97.56H $97.56L $90.80C $90.80VOL 1.32M
RES: $99.76SUP: $71.73SMA50: $80.13SMA200: $61.05
$102.5$85.74$68.94$52.14$35.34RES $99.76SUP $71.73$90.802026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KNSA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ KNSA Butterfly Map β†’ + Track KNSA β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
48.0%/yr Implied 5Y Growth

vs. +60.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on KNSA today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for KNSA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KNSA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KNSA)

Health Care Rank #68 of 1015 βš”οΈ IONS vs KNSA Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (KNSA vs. IONS, AMRX, ABVX, AXSM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Kiniksa Pharmaceuticals International plc (Class A) (KNSA) ranks #68 by composite RQD confidence (71/100, grade B-) and #131 by equity capitalization ($7.25B). Within this direct 5-issuer industry benchmark cohort, ABVX leads on earnings valuation at 32.8x trailing P/E, while AMRX leads on capital efficiency and profitability with 14.1% ROIC and 36.9% gross margin. KNSA currently leads its immediate peer cohort in composite quantitative strength at 71/100 (B-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
KNSA ACTIVE
Kiniksa Pharmaceuticals International plc (Class A)
B- 71/100 129.9x 88.5% 9.9% -1.56% $7.25B Benchmark Subject
IONS
Ionis Pharmaceuticals Inc.
E 26/100 β€” 96.0% -20.9% -5.24% $7.23B /ions-vs-knsa β†’
AMRX
Amneal Pharmaceuticals Inc.
B- 71/100 103.2x 36.9% 14.1% -4.97% $7.49B /amrx-vs-knsa β†’
ABVX
Abivax SA
D+ 54/100 32.8x β€” 9.9% -1.94% $7.56B /abvx-vs-knsa β†’
AXSM
Axsome Therapeutics Inc.
D- 35/100 β€” β€” -21.9% -5.83% $7.57B /axsm-vs-knsa β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001730430 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Kiniksa Pharmaceuticals International plc (Class A) (KNSA) reported GAAP revenue of $677.6M (+60.1% vs. FY2024 revenue of $423.2M , and +150.7% cumulative change since FY2023) , GAAP net income of $59.0M, operating cash flow of $138.0M, and free cash flow of $136.4M (+436.8% YoY). On the balance sheet, KNSA closed FY2025 with $763.6M in total assets against $88.2M in total debt (Altman Z-Score: 24.45, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $677.6M $59.0M $138.0M $136.4M $763.6M $88.2M
FY2024 (FY) 2024-12-31 $423.2M -$43.2M $25.7M $25.4M $580.6M $64.0M
FY2023 (FY) 2023-12-31 $270.3M $14.1M $13.3M $1.1M $4.22B $986.5M

3. KNSA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KNSA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Kiniksa Pharmaceuticals International plc (Class A) (NASDAQ: KNSA) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $90.80 (-1.56% 1D, market cap $7.25B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, KNSA ranks #68 in composite RQD confidence.

How does KNSA compare to IONS and AMRX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KNSA carries a Roarable B- (71/100 RQD), trailing P/E of 129.9x, gross margin of 88.5%, and ROIC of 9.9%. By comparison, IONS (Ionis Pharmaceuticals Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -20.9%, cap $7.23B) and AMRX (Amneal Pharmaceuticals Inc.) posts a B- grade (71/100 RQD, P/E 103.2x, ROIC 14.1%, cap $7.49B). Among the 5-stock peer group, ABVX leads on earnings multiple (32.8x) while AMRX leads on capital efficiency (14.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KNSA?

Per KNSA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001730430), Kiniksa Pharmaceuticals International plc (Class A) generated $677.6M in revenue (+60.1% YoY), $59.0M in net income, and $136.4M in free cash flow against $763.6M in total assets and $88.2M in total debt. Key quantitative strengths: Strong cash generator (88.5% gross margin)β€”profits are backed by real money, not accounting tricks. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KNSA trading relative to its 50-day, 200-day, and 52-week technical levels?

KNSA last traded at $90.80 (-1.56% on volume of 999,013 shares), positioning the stock +13.32% above its 50-day simple moving average ($80.13) and +48.73% above its 200-day simple moving average ($61.05). Across its 52-week range of $36.56 to $98.48, KNSA sits at the 87.6% percentile with a 14-day RSI of 59.2 (BULLISH MOMENTUM) and an implied next-earnings move of Β±10.4% ($81.36 to $100.24).

Direct Sub-Reports: KNSA RQD Cockpit KNSA 12M Forecast KNSA Earnings & Move KNSA Dividends & DRIP KNSA Insiders & 13F KNSA Whale Options KNSA Profit Sankey KNSA News & Why
ROARABLE RATING BRIEF β€’ RQD 71/100 (B-) βœ“ SEC XBRL & RQD VERIFIED

KNSA β€” Kiniksa Pharmaceuticals International plc (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Kiniksa Pharmaceuticals International plc (Class A) (KNSA) earns a live Roarable RQD composite score of 71/100, corresponding to a B- letter grade (Roarable Buy) at a spot price of $90.80 (-1.56% 1D, market capitalization $7.25B).

  • Fundamental Cash Engine (15/20): Anchored by return on invested capital (ROIC) of 9.9%, gross margin of 88.5%, operating margin of 11.4%, and free cash flow yield of 1.78%.
  • Whale 13F & Options Flow (18/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (14/20) + Forensic Balance Sheet (15/20): Incorporates a 1.11x equity beta, Altman Z-Score of 24.45, Piotroski F-Score of 9/9, and Debt/Equity of 0.15x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Kiniksa Pharmaceuticals International plc (Class A) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, and market profile. Specific product lines, customer base, and revenue model are β€” The source data reports gross margin of 88.5% and operating margin of 11.4%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Kiniksa Pharmaceuticals International plc (Class A) (KNSA) reported $677.6M in annual revenue (up from $423.2M in FY2024, +60.1% YoY) and $59.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($270.3M revenue, $14.1M net income) through FY2025, KNSA scaled operating cash flow to $138.0M and free cash flow to $136.4M, backed by $763.6M in total assets against $88.2M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (B- β€’ RQD 71/100): Strong cash generator (88.5% gross margin)β€”profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 15/20 and Institutional Whale Flow at 18/20, sustained execution supports upside toward the upper end of the $36.56 – $98.48 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 129.9x trailing P/E and 95.0x EV/EBITDA against 11.4% operating margins and a 1.11x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), KNSA carries a macro regime beta of 1.11 and gross margin of 88.5%.

  • Key Question #1: Can KNSA sustain or expand its 11.4% operating margin and 9.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $677.6M and free cash flow of $136.4M, how will capital allocation balance growth reinvestment against $88.2M in total debt?
  • Key Question #3: How sensitive is KNSA's 109.1x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.11x)?

KNSA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Kiniksa Pharmaceuticals International plc (Class A) (KNSA) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to KNSA Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KNSA Bull vs. Bear Conversation Board β€” What's Your Call at $90.80?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KNSA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on KNSA:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER β€’ FCF Compounder Hunter πŸ‚ BULLISH 🎯 Target: $112.53 (+22.0%)
πŸ“Œ Pinned Debate

Strong balance sheet (Piotroski 9/9, Altman Z 24.45) plus institutional accumulation (18/20 whale pillar) and FY 2025 revenue of $677.6

Picked up a starter position in KNSA in my $100K Virtual Cash book at $92.24. Strong balance sheet (Piotroski 9/9, Altman Z 24.45) plus institutional accumulation (18/20 whale pillar) and FY 2025 revenue of $677.6M versus $423.2M in FY 2024.. Trading inside a $37.02–$98.48 52-week range with 1.78% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

RetailWhale_TX πŸ‚ BULL

@CreditSpread_Watch Shorting a 18/20 institutional whale-flow stock at $92.24 is dangerous when funds are rotating into Health Care.

CR CreditSpread_Watch RQD DEBATE OPENER β€’ Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $76.56 (-17.0%)
Spot @ $92.24

Valuation of 129.9x TTM P/E and a 1.78% FCF yield leave little margin for error, with insider conviction scoring only 9/20.

Valuation of 129.9x TTM P/E and a 1.78% FCF yield leave little margin for error, with insider conviction scoring only 9/20.. Look at the math on KNSA: paying 129.9x trailing P/E for 9.9% ROIC and 11.4% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $81.17 before getting long.

LIVE TAPE